<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116016">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01923168</url>
  </required_header>
  <id_info>
    <org_study_id>CBYL719A2201</org_study_id>
    <nct_id>NCT01923168</nct_id>
  </id_info>
  <brief_title>Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women</brief_title>
  <official_title>A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Austria: Ethikkommission</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Brazil: Ministry of Health</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Colombia: National Institutes of Health</authority>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <authority>Germany: German Institute of Medical Documentation and Information</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Lebanon: Ministry of Public Health</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether treatment with a PI3K inhibitor plus
      letrozole leads to an increase in pathologic response compared to treatment with placebo
      plus letrozole in patients with Breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pathological Complete Response</measure>
    <time_frame>After 24 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure Pathological complete Response after 24 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate according to  RECIST 1.1 criteria</measure>
    <time_frame>After 24 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective response rate according to  RECIST 1.1 criteria after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity, of AEs and lab abnormalities</measure>
    <time_frame>During 24 weeks of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the safety and tolerability of study treatment based on the frequency, severity AEs, lab abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate breast conserving surgery</measure>
    <time_frame>After 24 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of breast conserving surgery, following completion of 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular markers and correlation with response</measure>
    <time_frame>Baseline, Day 15 and 24 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation between pCR and change in Ki67 from baseline to day 15 and baseline to surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEPI (preoperative endocrine prognostic index) score</measure>
    <time_frame>After 24 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the Preoperative endocrine prognostic index (PEPI) score after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of BYL719/buparlisib and letrozole when given in combination</measure>
    <time_frame>Cycle 1 (Day 1, 2, 8, 15, 22), Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4(Day 1 and Day 2), Cycle 5 Day 1 and Cycle 6 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentration time profiles of BYL719/buparlisib and appropriate individual PK parameters Plasma concentration time profiles of letrozole and appropriate individual PK parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>BYL719 + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL719 + Letrozole in 120 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buparlisib + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buparlisib + Letrozole in 120 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Letrozole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (of Buparlisib or BYL719 ) with Letrozole in 120 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719</intervention_name>
    <description>BYL719 + Letrozole</description>
    <arm_group_label>BYL719 + Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120</intervention_name>
    <description>BKM120 + Letrozole</description>
    <arm_group_label>Buparlisib + Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (of BYL719 or BKM120) + Letrozole</description>
    <arm_group_label>Placebo + Letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is an adult, female ≥ 18 years old at the time of informed consent

          2. Patient has a histologically and/or cytologically confirmed diagnosis of breast
             cancer

          3. Patient is postmenopausal.

          4. Patient has T1c-T3, any N, M0, operable breast cancer

          5. Patients must have measurable disease

          6. Patient has diagnostic biopsy available for the analysis of PIK3CA mutation and Ki67
             level.

          7. Patient has estrogen-receptor and/or progesterone positive breast cancer as per local
             laboratory testing

          8. Patient has HER2 negative breast cancer defined as a negative in situ hybridization
             test or an IHC status of 0 or 1+ as per local laboratory testing

             -

        Exclusion Criteria:

          1. Patient has locally recurrent or metastatic disease

          2. Patient has received any systemic therapy (e.g. chemotherapy, targeted therapy,
             immunotherapy) or radiotherapy for current breast cancer disease before study entry.

          3. Patient with clinically manifest diabetes mellitus (fasting glucose &gt; 120 mg/dl or
             6.7 mmol/L), or documented steroid induced diabetes mellitus

          4. Certain scores on an anxiety and depression mood questionnaires

          5. Other protocol-defined inclusion/exclusion criteria may apply

             -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham/ Kirklin Clinic Univ AL - PI</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla Perna</last_name>
      <phone>205-934-0337</phone>
      <email>carla.perna@ccc.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero-Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona / Arizona Cancer Center BYL791A2201</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dana Lewallen</last_name>
      <phone>520-626-2175</phone>
      <email>dlewallen@azcc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Pavani Chalasani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group Dept of Highlands Oncology Grp</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holly Kinser</last_name>
      <phone>479-872-8130</phone>
      <email>hkinser@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>Thaddeus J Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles UCLA SC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Kelly</last_name>
      <phone>310-582-6324</phone>
      <email>kmkelly@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sara Hurvitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center SC</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelica Ruiz</last_name>
      <phone>760-416-4736</phone>
      <email>angelica.ruiz@tenethealth.com</email>
    </contact>
    <investigator>
      <last_name>Scott S Brook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco BYL719A2201 - SC</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-885-3789</phone>
    </contact>
    <investigator>
      <last_name>Hope S. Rugo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Pacific Medical Foundation</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Devisser</last_name>
      <phone>707-576-4738</phone>
      <email>devissc@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Eric W. Dean</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute BYL719A2201</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nwaugo Ogbonnaya</last_name>
      <phone>404-778-4824</phone>
      <email>nwaugo.ogbonnaya@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Ruth M. O'Regan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francis De Leon</last_name>
      <phone>312-695-1382</phone>
      <email>ctpathcore@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>William J. Gradishar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robbie Comito</last_name>
      <phone>317-278-6680</phone>
      <email>rcomito@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Anna Storniolo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Johns Hopkins Med. BYL719A2201</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacie Jeter</last_name>
      <phone>410-614-6138</phone>
      <email>sjeter1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio C. Wolff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute BYL719A2201</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Ryabin</last_name>
      <phone>617-632-2335</phone>
      <email>nryabin@partners.org</email>
    </contact>
    <investigator>
      <last_name>Nancy Uan-Tsin Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester BYL719A2201 - SC</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Szumlanski</last_name>
      <phone>507-266-0539</phone>
      <email>szumlanski.carol@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Minetta C. Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jasmine Rizzo</last_name>
      <phone>732-235-7577</phone>
      <email>rizzoji@umdnj.edu</email>
    </contact>
    <investigator>
      <last_name>Antoinette R. Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina UNC 2</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Phipps</last_name>
      <phone>+1 919 966 4432</phone>
      <email>rachel_phipps@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>E Claire Dees</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delinda Phillips</last_name>
      <phone>919-660-1278</phone>
      <email>delinda.phillips@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Kimberly Blackwell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Magee Womens Hospital BYL719A2201</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rometa Pollard</last_name>
      <phone>412-641-2261</phone>
      <email>pollardrr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Shannon Puhalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center Vanderbilt Health 100 Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Scott</last_name>
      <phone>615-936-1164</phone>
      <email>Julie.scott.1@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Ingrid Mayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Oncology Central Monitoring</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela Westerhold</last_name>
      <email>DIWesterhold@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Stacy Moulder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research SC-3</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Takahashi</last_name>
      <phone>206-288-1254</phone>
      <email>missyt@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Hanna Linden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties Dept.ofNW Med. Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Betsy McQuire</last_name>
      <phone>253-396-5329</phone>
      <email>bmcquire@nwmsonline.com</email>
    </contact>
    <investigator>
      <last_name>Sibel Blau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6005</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leoben</city>
        <zip>A-8700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <zip>00000</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Besançon cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cremona</city>
        <state>CR</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Macerata</city>
        <state>MC</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terni</city>
        <state>TN</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0081</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2192</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Sebastian</city>
        <state>Pais Vasco</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>August 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer, Pathological Complete Response, neoadjuvant, hormone receptor-positive</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
